rajan Profile
rajan

@rajanyadav

Followers
95
Following
57
Media
84
Statuses
468

Maverick Med & HematoOncologist .

Ahmadabad City, India
Joined February 2010
Don't wanna be here? Send us removal request.
@rajanyadav
rajan
5 days
RT @ArndtVogel: šŸ”„off the press, now fully published.Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and….
0
53
0
@rajanyadav
rajan
6 days
RT @myESMO: šŸ“£ Updated ESMO #ClinicalPracticeGuideline recommendations in #MetastaticBreastCancer: focusing on #PrecisionOncology and a #Pat….
0
9
0
@grok
Grok
8 days
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
413
690
3K
@rajanyadav
rajan
6 days
RT @dr_yakupergun: Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline†. http….
0
34
0
@rajanyadav
rajan
23 days
RT @Timothee_MD: Academic read of the day!. Crossover in oncology? . A concise, open-access, 2-page paper clearly framing when it is is des….
0
20
0
@rajanyadav
rajan
28 days
RT @UrogerliMD: @TiansterZhang caught me up on the last decade of #RCC research in 20 mins! @ANZUPtrials #anzup25
Tweet media one
Tweet media two
Tweet media three
Tweet media four
0
8
0
@rajanyadav
rajan
28 days
RT @HHorinouchi: šŸ”„BREAKINGšŸ†™ Positive OSā€¼ļø.āœ…FLAURA2: Osimertinib + Chemo vs Osimertinib.šŸŽÆ"Statistically significant and clinically meaningfu….
astrazeneca.com
0
37
0
@rajanyadav
rajan
28 days
RT @dr_yakupergun: FLAURA-2: Osimertinib + chemo significantly improves OS in EGFR-mutated advanced lung cancer. After MARIPOSA, another….
0
19
0
@rajanyadav
rajan
1 month
RT @medoncodoc: ASCO updates stage IV NSCLC with driver mutation guideline. #lcsm .
Tweet media one
Tweet media two
0
4
0
@rajanyadav
rajan
1 month
RT @medoncodoc: 🫁 HMGB1 as a Biomarker for Severe Checkpoint Inhibitor Pneumonitis (CIP): A Prospective Study. šŸ“ Background:.Severe checkpo….
0
2
0
@rajanyadav
rajan
2 months
RT @medoncodoc: 🧫 Real-world outcomes of teclistamab in MM with prior BCMA-directed therapy (BCMA-DT):. šŸ“Œ Among 385 patients, 50% had prior….
0
1
0
@rajanyadav
rajan
2 months
RT @medoncodoc: 🧬🫁 Structure Matters in Compound EGFR-Mutant NSCLC. šŸ“Š Multicenter study (n=81) in advanced NSCLC w/ compound EGFR mutations….
0
5
0
@rajanyadav
rajan
2 months
RT @DrYukselUrun: p-value decoding guide:.0.0000000001 Nobel šŸ„‡.0.049 šŸ¾.0.050 😬 redo math.0.06 ā€œTrending towardā€¦ā€.0.08 p < 0.10? Why not?.≄0….
0
7
0
@rajanyadav
rajan
2 months
RT @medoncodoc: Important data for LMIC and resource constrained setting from PGI Chandigarh!.@DrGPrakash @DrPMPGI . Ven 50 mg + Posa gener….
0
5
0
@rajanyadav
rajan
2 months
RT @medoncodoc: 🧬 ICIs in Solid Organ Transplant Recipients (SOTRs) 🧫🧔. šŸ“Š Meta-analysis of 343 SOTRs with advanced cancers treated with imm….
0
1
0
@rajanyadav
rajan
2 months
RT @medoncodoc: 🧬 Liquid Biopsy-Based Multi-Cancer Early Detection (MCED): Hype or Hope? 🧫.MCED tests aim to detect multiple cancers in ear….
0
1
0
@rajanyadav
rajan
2 months
For 3 years, @Airtel_Presence you’ve been spamming me with emails for numbers I don’t own. I’ve DM’d screenshots countless times. If you can’t stop spamming your own customers, how do you claim to block spam for others? #Irony #Fail.
2
0
1
@rajanyadav
rajan
2 months
RT @medoncodoc: A nice review on Postmastectomy RT and RNI in the era of de-escalation of treatment .#bcsm . @Erika….
0
23
0
@rajanyadav
rajan
2 months
RT @TheLancet: šŸ—Øļø ā€œVaccines have done more to improve public health than any other medical intervention.ā€. A new Viewpoint focuses on cance….
0
458
0
@rajanyadav
rajan
2 months
RT @OscarTahuahua: After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor–Positive Metastatic Breast Cancer ..
0
85
0
@rajanyadav
rajan
2 months
RT @PaulJiL: šŸ’„Neoadjuvant pembrolizumab has received the approval for PDL1 CPS≄1 head&neck SCC by FDA! . šŸ›ŽļøThis will require quick CPS test….
0
18
0